Clinical Trials Browser

Phase 2 × Cholangiocarcinoma × infigratinib × Clear all

NCT04233567 2026-02-24

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Phase 2 Completed

17 enrolled 12 charts

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Phase 2 Withdrawn

Gastrointestinal

Cholangiocarcinoma